Market Place
Sourcing Support
Mirati`s wait for next lung cancer med ends in phase 3 failure
25 May 2023 //
FIERCE BIOTECH
Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study
24 May 2023 //
PRESS RELEASE
Mirati`s sitravatinib yet to improve survival at interim review
02 Dec 2022 //
FIERCEBIOTECH
Mirati Therapeutics Presents Ph2 Data On Sitravatinib With Nivolumab
18 Sep 2020 //
BIOSPACE
Mirati`s Announces Initial Data In RCC a Sitravatinib In Combination
17 Feb 2020 //
PR NEWSWIRE
Mirati Therapeutics Announces Presentation Of Interim Phase 2 Sitravatinib
24 Oct 2019 //
PR NEWSWIRE
Mirati Presents Ph 2 Clinical Trial Of Sitravatinib+Nivolumab
10 Nov 2018 //
PR NEWSWIRE
Mirati`s Patient Dosed In Ph1b Clinical Trial Of Sitravatinib+ Tislelizumab
10 Nov 2018 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.